


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**INNOVATIVE DRUG “TQ-B3525” WAS INCLUDED IN THE LIST OF  
BREAKTHROUGH THERAPY DRUGS BY CDE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “TQ-B3525”, an innovative drug self-developed by the Group, has been included by the Center for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration of China in the list of breakthrough therapy drugs. The indication is relapsed/refractory follicular lymphoma that has failed at least two prior lines of therapy.

TQ-B3525 is a novel and selective oral PI3K (phosphatidylinositol 3-kinase)  $\alpha / \delta$  inhibitor. Studies have shown that PI3K is closely associated with tumours. TQ-B3525 is a dual inhibitor of PI3K catalytic subunits  $\alpha / \delta$ . It can not only overcome the drug resistance problem caused by the increase of PI3K  $\alpha$  subunit activity when inhibiting PI3K  $\delta$  subunit alone, but also significantly reduce the toxicity compared with PI3K pan-inhibitors. Currently, the Group has initiated a number of clinical studies on TQ-B3525 in China, mainly targeting haematological tumours, and some of them have entered Phase II clinical trials.

The CDE has established the Procedure for Breakthrough Therapy Drugs to encourage research and development of new drugs to meet clinical needs and to expedite the review and approval of new drug varieties. Follow-up communication and review and approval of the innovative drugs that have been included as breakthrough therapy drugs can be carried out in accordance with the accelerated procedures.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 8 April 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*